CureApp, Inc. implemented a third party allotment of new shares totaling 380 million JPY

CureApp, Inc. (headquartered in Chuo-ku, Tokyo: President and CEO: Kota Satake) which is engaged in the research and development of therapeutic applications as medical devices as well as their manufacture and sale, has today announced that Beyond Next Ventures and Keio Innovation has implemented a third party allotment capital of 380 million JYN taken on by SBI Investments.

[Overview of Underwrite]
Beyond Next Ventures
Head Office: 1-4-3 Nihonbashi Honcho, Chuo-ku, Tokyo
Representative Director and President: Takeshi Ito

Keio Innovation Initiative
Headquarters: Mita 1-4-28, Minato-ku, Tokyo
Representative Director: Hirotaro Yamagishi

SBI Investment
Head office: 1-6-1 Roppongi, Minato-ku, Tokyo
Representative Director and Executive Officer President: Katsuya Kawashima



[Implementation Background and Objectives]
CureApp aims to create individually optimized (personalized) medical care that achieves a superb therapeutic effect as a form of new medical treatment by utilizing the evolution of mobile technology.
Specifically, it involves intervention treatment using a "treatment application" for a wide range of patient needs, including patient awareness, behavioral habits and time frames (such as time spent out-of-hospital, at home or when going out). We are building a mechanism to appropriately and accurately follow the patient according to their current condition.
Due to the way in which the current discussion regarding the use of ICT, AI, etc. for medical care and nursing care in Japanese society is progressing, our company‘s image of the future coincides with the needs of the nation of Japan. Due to this result, we have provided an increase in capital to promote our research and development for the future.

[About CureApp, Inc.]

CureApp, Inc. is a MedTech venture from R & D to manufacturing and sales of medical treatment equipment based on advanced software technology and medical evidence. In order to realize a new medical service in Japan where "an application has the effect of treating diseases" for the first time, we are working on the development of a "treatment application" which is an application for the treatment of diseases.

The “treatment application" aims to generate a new effect on treatment using analysis and guidance by an application based on medical knowledge and evidence based on the daily treatment course of each patient. It also has the possibility of contributing to the fundamental improvement of disease treatment by encouraging the improvement of patient behavioral habits from the alteration of awareness and behavior. In Japan, we have begun clinical trials early and have started applying them to multiple diseases




The development status of the current "treatment application" is as follows:
■ “Treatment Application” of nicotine addiction: Joint development with respiratory internal medicine department of Keio University School of Medicine, multicenter cooperative clinical trial has been in progress since February 2015.
■ “Nonalcoholic steatohepatitis (NASH) Treatment Application”: Collaborative research with the Tokyo University Hospital affiliated hospital. Clinical research has been in progress since October 2016.

"Treatment Application" is a registered trademark of CureApp Co., Ltd.

[CureApp Company Outline]
Company Name: CureApp Inc. (CureApp, Inc.)
Representative Director and President: Kota Satake
Head Office: Nihonbashi Koibu-cho, Chuo-ku, Tokyo No. 1 CASTELLINO O.T. NIHONBASHI 7th Floor
Capital and Capital Reserves: 484,100,000 JPY
Establishment: July 31, 2014
Business Description: Medical Equipment Development, PHR (Personal Health Record) Business, Mobile Health Related Service Business
Trademark Registration: "treatment application" "CureApp"
URL: http://cureapp.co.jp/



[Inquiries Concerning this Matter]
CureApp, Inc.
Public Relations: Mishima
support@cureapp.jp